eflornithine has been researched along with Melanoma in 33 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the present study was to investigate the effect of polyamine depletion by alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, on the growth and differentiation of B16 melanoma cells grown in culture and also as solid tumors in mice." | 7.67 | Effect of inhibition of polyamine biosynthesis by DL-alpha-difluoromethylornithine on the growth and melanogenesis of B16 melanoma in vitro and in vivo. ( Chang, CC; Lachmann, PJ; Prakash, NJ; Sunkara, PS, 1985) |
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 5.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| " Although the three sublines were 2- to 10-fold less sensitive than the parent line to classical MDR-type agents, they were found in dose-response studies to be significantly more sensitive to DENSPM than the parent line." | 5.29 | Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine. ( Bergeron, RJ; Ganis, B; Kramer, DL; Porter, CW; Rustum, Y; Wrzosek, C, 1994) |
| " Median effect analysis of the DFMO + IFN inhibition of C8161 cells demonstrated that the 2 agents interacted synergistically over the entire dose-response curve." | 5.27 | Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid. ( Bregman, MD; Meyskens, FL, 1986) |
| "Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, and human leukocyte interferon (IFN-alpha) have synergistic anti-tumor activities in vivo in B 16 melanoma and in vitro against several human cancer cell lines." | 3.67 | Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients. ( Benjamin, R; Gutterman, J; Kantarjian, H; Plager, C; Quesada, J; Talpaz, M, 1986) |
| "The objective of the present study was to investigate the effect of polyamine depletion by alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ornithine decarboxylase, on the growth and differentiation of B16 melanoma cells grown in culture and also as solid tumors in mice." | 3.67 | Effect of inhibition of polyamine biosynthesis by DL-alpha-difluoromethylornithine on the growth and melanogenesis of B16 melanoma in vitro and in vivo. ( Chang, CC; Lachmann, PJ; Prakash, NJ; Sunkara, PS, 1985) |
| "alpha-Difluoromethyl ornithine and mouse type 1 interferon, when administered simultaneously, were highly toxic to B16 melanoma cells in culture." | 3.66 | Tumor suppression with a combination of alpha-difluoromethyl ornithine and interferon. ( Mayer, GD; Prakash, NJ; Sjoerdsma, A; Sunkara, PS, 1983) |
| "An exposure of cultured Cloudman S91 melanoma cells to inhibitors of polyamine biosynthesis, 2-difluoromethylornithine (DFMO) and methylglyoxal bis(guanylhydrazone) (MGBG), distinctly promoted the expression of differentiated biochemical functions of the tumor cells." | 3.66 | Stimulation of melanotic expression in murine melanoma cells exposed to polyamine antimetabolites. ( Jänne, J; Käpyaho, K, 1983) |
| "The incidence of skin cancer (both melanoma and non-melanoma) continues to grow at an alarming rate." | 2.41 | The state-of-the-art in chemoprevention of skin cancer. ( Alberts, DS; Dorr, RT; Stratton, SP, 2000) |
| "Melanoma is a disease that need not be deadly." | 2.38 | The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening. ( Greene, MH, 1993) |
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 1.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| " Although the three sublines were 2- to 10-fold less sensitive than the parent line to classical MDR-type agents, they were found in dose-response studies to be significantly more sensitive to DENSPM than the parent line." | 1.29 | Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine. ( Bergeron, RJ; Ganis, B; Kramer, DL; Porter, CW; Rustum, Y; Wrzosek, C, 1994) |
| "When tilorone was given 7 days after tumor inoculation, it did not show any potentiation of antitumor activity of DFMO." | 1.27 | Potentiation of antitumor and antimetastatic activities of alpha-difluoromethylornithine by interferon inducers. ( Hagan, AC; Lachmann, PJ; Mayer, GD; Prakash, NJ; Rosenberger, AL; Sunkara, PS, 1984) |
| " Median effect analysis of the DFMO + IFN inhibition of C8161 cells demonstrated that the 2 agents interacted synergistically over the entire dose-response curve." | 1.27 | Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid. ( Bregman, MD; Meyskens, FL, 1986) |
| "The in vivo growth of ascite plasmocytoma of solid melanoma B-16 cells in mice was also effectively inhibited by DFMO." | 1.27 | [Antiproliferative activity of difluoromethylornithine and the factors decreasing its effectiveness in malignant growth]. ( Diachok, FI; Gridina, NIa; Khomenko, AK; Kudriavets, IuI; Semeniĭ, VIa, 1986) |
| " A dose-response curve was developed for each interferon in which the maximum dose applied gave at least 30% growth inhibition of control values after 96-128 h of continuous exposure." | 1.27 | The in vitro interaction of alpha-difluoromethyl ornithine (DFMO) and several interferons on human cell lines. ( Harvey, HA; Leitzel, KE; Lipton, A; Pegg, AE; Wolf, LM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (63.64) | 18.7374 |
| 1990's | 8 (24.24) | 18.2507 |
| 2000's | 3 (9.09) | 29.6817 |
| 2010's | 1 (3.03) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pommergaard, HC | 1 |
| Burcharth, J | 1 |
| Rosenberg, J | 1 |
| Raskov, H | 1 |
| Sunkara, PS | 8 |
| Prakash, NJ | 5 |
| Mayer, GD | 2 |
| Sjoerdsma, A | 3 |
| Käpyaho, K | 2 |
| Jänne, J | 2 |
| Schechter, PJ | 1 |
| Nishioka, K | 1 |
| Rosenberger, AL | 4 |
| Hagan, AC | 1 |
| Lachmann, PJ | 2 |
| Porter, CW | 3 |
| Ganis, B | 1 |
| Rustum, Y | 1 |
| Wrzosek, C | 1 |
| Kramer, DL | 2 |
| Bergeron, RJ | 1 |
| Greene, MH | 1 |
| Gerner, EW | 2 |
| Kurtts, TA | 1 |
| Fuller, DJ | 2 |
| Casero, RA | 1 |
| Shappell, NW | 1 |
| Fogel-Petrovic, MF | 1 |
| Stratton, SP | 1 |
| Dorr, RT | 1 |
| Alberts, DS | 1 |
| Weeks, RS | 1 |
| Vanderwerf, SM | 1 |
| Carlson, CL | 1 |
| Burns, MR | 1 |
| O'Day, CL | 1 |
| Cai, F | 1 |
| Devens, BH | 1 |
| Webb, HK | 1 |
| Chang, BD | 1 |
| Chen, Y | 1 |
| Diegelman, P | 1 |
| Alm, K | 1 |
| Black, AR | 1 |
| Roninson, IB | 1 |
| Croghan, MK | 3 |
| Aickin, MG | 1 |
| Meyskens, FL | 6 |
| Creagan, ET | 2 |
| Long, HJ | 1 |
| Ahmann, DL | 2 |
| Schaid, DJ | 2 |
| Harari, PM | 1 |
| Carper, SW | 1 |
| Shimm, DS | 1 |
| Frytak, S | 1 |
| Endo, Y | 1 |
| Matsushima, K | 1 |
| Onozaki, K | 1 |
| Oppenheim, JJ | 1 |
| Bregman, MD | 2 |
| Bowlin, TL | 2 |
| McKown, BJ | 1 |
| Davis, GF | 1 |
| Khomenko, AK | 1 |
| Semeniĭ, VIa | 1 |
| Gridina, NIa | 1 |
| Diachok, FI | 1 |
| Kudriavets, IuI | 1 |
| Talpaz, M | 1 |
| Plager, C | 1 |
| Quesada, J | 1 |
| Benjamin, R | 1 |
| Kantarjian, H | 1 |
| Gutterman, J | 1 |
| Kubota, S | 1 |
| Ohsawa, N | 1 |
| Takaku, F | 1 |
| Kingsley, EM | 1 |
| Glattke, T | 1 |
| Loescher, L | 1 |
| Booth, A | 2 |
| Niederkorn, JY | 1 |
| Sanborn, GE | 1 |
| Gamel, JW | 1 |
| Buckmeier, J | 1 |
| Funk, C | 1 |
| Sinervirta, R | 1 |
| Chang, CC | 1 |
| Wolf, LM | 1 |
| Leitzel, KE | 1 |
| Pegg, AE | 1 |
| Harvey, HA | 1 |
| Lipton, A | 1 |
3 reviews available for eflornithine and Melanoma
| Article | Year |
|---|---|
Chemotherapeutic implications of polyamine biosynthesis inhibition.
Topics: Animals; Drug Evaluation; Eflornithine; Female; Humans; Male; Melanoma; Mice; Middle Aged; Ornithine | 1984 |
The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening.
Topics: Animals; Anticarcinogenic Agents; Dysplastic Nevus Syndrome; Eflornithine; Fluorouracil; Humans; Mas | 1993 |
The state-of-the-art in chemoprevention of skin cancer.
Topics: Animals; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Eflornithine; Humans; Melano | 2000 |
1 trial available for eflornithine and Melanoma
| Article | Year |
|---|---|
Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Drug Evaluation; Eflornithine; Fe | 1990 |
29 other studies available for eflornithine and Melanoma
| Article | Year |
|---|---|
Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Calcitriol; Chemoprevention; D | 2013 |
Tumor suppression with a combination of alpha-difluoromethyl ornithine and interferon.
Topics: Animals; Cells, Cultured; Eflornithine; Interferons; Melanoma; Mice; Neoplasms, Experimental; Ornith | 1983 |
Stimulation of melanotic expression in murine melanoma cells exposed to polyamine antimetabolites.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Division; Cell Line; Drug Synergism; Eflo | 1983 |
Potentiation of antitumor activity of alpha-difluoromethyl ornithine by the immunomodulating peptide tuftsin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Eflo | 1983 |
Potentiation of antitumor and antimetastatic activities of alpha-difluoromethylornithine by interferon inducers.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Drug Synergism; Eflornithine; Fluorenes; L | 1984 |
Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine.
Topics: Adenosylmethionine Decarboxylase; Amidines; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 1994 |
Stress induction of the spermidine/spermine N1-acetyltransferase by a post-transcriptional mechanism in mammalian cells.
Topics: Acetylation; Acetyltransferases; Animals; CHO Cells; Cricetinae; Ditiocarb; Eflornithine; Enzyme Ind | 1993 |
Regulation of spermidine/spermine N1-acetyltransferase by intracellular polyamine pools. Evidence for a functional role in polyamine homeostasis.
Topics: Acetyltransferases; Blotting, Northern; Eflornithine; Gene Expression Regulation, Enzymologic; Homeo | 1993 |
Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO.
Topics: Animals; Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cell Division; Eflornithine; | 2000 |
Polyamine depletion in human melanoma cells leads to G1 arrest associated with induction of p21WAF1/CIP1/SDI1, changes in the expression of p21-regulated genes, and a senescence-like phenotype.
Topics: Adenosylmethionine Decarboxylase; Biogenic Polyamines; Cell Cycle; Cell Division; Cellular Senescenc | 2001 |
Dose-related alpha-difluoromethylornithine ototoxicity.
Topics: Adolescent; Adult; Age Factors; Aged; Audiometry; Dose-Response Relationship, Drug; Drug Evaluation; | 1991 |
Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Eflornithine; Female; | 1990 |
Polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy.
Topics: Acetylation; Animals; Cell Survival; Combined Modality Therapy; Cricetinae; Cricetulus; Eflornithine | 1990 |
Role of ornithine decarboxylase in the regulation of cell growth by IL-1 and tumor necrosis factor.
Topics: Animals; Cell Division; Cell Line; DNA; Eflornithine; Glioma; Growth Inhibitors; Humans; Interleukin | 1988 |
Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid.
Topics: Cell Line; Cell Survival; Dexamethasone; Drug Combinations; Drug Synergism; Eflornithine; Humans; In | 1986 |
The effect of alpha-difluoromethylornithine on natural killer cell and tumoricidal macrophage induction by interferon in vivo.
Topics: Animals; Cytotoxicity, Immunologic; Eflornithine; Interferon Type I; Killer Cells, Natural; Macropha | 1986 |
[Antiproliferative activity of difluoromethylornithine and the factors decreasing its effectiveness in malignant growth].
Topics: Animals; Antineoplastic Agents; Bacillus megaterium; Cell Division; Cells, Cultured; Dose-Response R | 1986 |
Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Eflornithine; Female; Gastrointestinal Diseases | 1986 |
Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice.
Topics: Animals; Eflornithine; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neop | 1987 |
Effects of DL-alpha-difluoromethylornithine on the growth and metastasis of B16 melanoma in vivo.
Topics: Animals; Eflornithine; Female; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Polyamines | 1987 |
A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Eflornithine; Female; Hearing; Humans; Male; Me | 1986 |
Suicide enzyme inhibition as a chemotherapeutic strategy for controlling metastases derived from intraocular melanomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eflornithine; Enzyme Inhibitor | 1987 |
A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma.
Topics: Adult; Aged; Combined Modality Therapy; Drug Evaluation; Eflornithine; Female; Humans; Interferon Ty | 1988 |
Median effect and long term recovery analysis of biological modifier interactions with difluoromethylornithine on the proliferation of human melanoma cells.
Topics: Cell Division; Cell Line; Culture Techniques; Dexamethasone; Eflornithine; Humans; Interferon Type I | 1987 |
Effects of inhibitors of polyamine biosynthesis on the growth and melanogenesis of murine melanoma cells.
Topics: Animals; Cell Division; Cells, Cultured; Eflornithine; Guanidines; Melanins; Melanoma; Mice; Mitogua | 1985 |
Potentiation by alpha-difluoromethylornithine of the activity of 3,4-dihydroxybenzylamine, a tyrosinase-dependent melanolytic agent, against B16 melanoma.
Topics: Catechol Oxidase; Cells, Cultured; Dopamine; Drug Synergism; Eflornithine; Humans; Melanoma; Monophe | 1985 |
Effect of inhibition of polyamine biosynthesis by DL-alpha-difluoromethylornithine on the growth and melanogenesis of B16 melanoma in vitro and in vivo.
Topics: Animals; Cell Division; Cells, Cultured; Eflornithine; Male; Melanins; Melanoma; Mice; Mice, Inbred | 1985 |
The in vitro interaction of alpha-difluoromethyl ornithine (DFMO) and several interferons on human cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line; Cell Survival; Drug Interactions; | 1985 |
The effect of combination treatment with alpha-difluoromethylornithine and Corynebacterium parvum on B16 melanoma growth and tumoricidal effector cell generation in vivo.
Topics: Animals; Eflornithine; Immunity, Cellular; Immunity, Innate; Immunotherapy; Killer Cells, Natural; M | 1985 |